Applications of 'decisionable biomarkers in cardiovascular drug development

Biomarkers in Medicine

Volumn 4, Issue 6, 2010, Pages 815-827

  Krishna, Rajesh ^b   Wagner, John A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NONE

Author keywords

cardiovascular; disease progression; distal biomarkers; proximal biomarkers

Indexed keywords

ALISKIREN; ANACETRAPIB; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ATORVASTATIN; BIOLOGICAL MARKER; CARDIOVASCULAR AGENT; CHOLESTEROL ESTER TRANSFER PROTEIN; DALCETRAPIB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 109; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MK 0354; NICOTINIC ACID; PLACEBO; TORCETRAPIB; UNCLASSIFIED DRUG;

ANGINA PECTORIS; ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CLINICAL PROTOCOL; CLINICAL RESEARCH; CORONARY ARTERY ATHEROSCLEROSIS; DEATH; DIABETIC NEPHROPATHY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DYSLIPIDEMIA; FLUSHING; HEART FAILURE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; KIDNEY BLOOD FLOW; LIFESTYLE MODIFICATION; LIPID METABOLISM; MEDICAL DECISION MAKING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PLASMA RENIN ACTIVITY; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE;

ANIMALS; BIOMARKERS, PHARMACOLOGICAL; CARDIOVASCULAR AGENTS; DECISION TREES; DRUG DISCOVERY; HUMANS;

EID: 78650727768     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.10.107     Document Type: Review

References (46)

1. Biomarker Defnitions Working Group: Biomarkers and surrogate end points: preferred defnition and conceptual framework. Clin. Pharmacol. Ther. 69, 89-95 (2001).
2. Wagner JA: Strategic approach to ft-for-purpose biomarkers in drug development. Annu. Rev. Pharmacol. Toxicol. 48, 631-651 (2008).
3. Krishna R, Herman G, Wagner JA: Accelerating drug development using biomarkers: a case study with sitagliptin, a novel DPP4 inhibitor for Type 2 diabetes. AAPS J. 10(2), 401-409 (2008).
4. Krishna R, Schaefer HG, Bjerrum OJ: Effective integration of systems biology, biomarkers, biosimulation and modeling in streamlining drug development. Eur. J. Pharm. Sci. 31, 62-67 (2007). (Pubitemid 46601868)
5. Cartwright ME, Cohen S, Fleishaker JC et al.: Proof of concept: a PhRMA position paper with recommendations for best practice. Clin Pharmacol Ther. 87(3), 278-285 (2010).
6. Wagner JA: Overview of biomarkers and surrogate end points in drug development. Dis. Markers 18, 41-46 (2002).
7. Williams SA, Slavin DE, Wagner JA, Webster CJ: A cost-effectiveness approach to the qualifcation and acceptance of biomarkers. Nat. Rev. Drug Discov. 5(11), 897-902 (2006).
8. Poland B, Hodge LF, Khan AA et al.: The clinical utility index as a practical multiattribute approach to drug development decisions. Clin. Pharmacol. Ther. 86(1), 105-108 (2009).
9. Khan AA, Perlstein I, Krishna R: The use of clinical utility assessments in early clinical development. AAPS J. 11(1), 33-38 (2009).
10. Khan A, Gould L, Saltzman JS, Wagner JA, Krishna R: A proposed quantitative framework for enabling decision making in early clinical development using analytic hierarchy process (AHP). Clin. Pharmacol. Ther. 87(S1), S72 (2010).
11. Lalonde RL, Kowalski KG, Hutmacher MM et al.: Model-based drug development. Clin. Pharmacol. Ther. 82, 21-32 (2007).
12. Stamler J, Wentworth D, Neaton JD: Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Finding in 356,222 primary screens of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 256(20), 2823-2828 (1986).
13. Knopp R: Drug treatment of lipid disorders. N. Engl. J. Med. 341, 498-511 (1999).
14. Tall AR: Plasma cholesteryl ester transfer protein. J. Lipid Res. 34, 1255-1274 (1993).
15. Koizumi J, Mabuchi H, Yoshimura A et al.: Defciency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinaemia. Atherosclerosis 58, 175-186 (1985).
16. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF et al.: Effcacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized Phase II dose-response study. Circulation 105, 2159-2165 (2002).
17. Clark RW, Sutfn TA, Ruggeri RB et al.: Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arteroscler. Thromb. Vasc. Biol. 24, 490-497 (2004).
18. Krishna R, Anderson MS, Bergman AJ et al.: Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled Phase I studies. Lancet 370, 1907-1914 (2007).
19. Barter PJ, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ, Tall AR: Cholesterol ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 23, 160-167 (2003).
20. Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H: A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 406, 203-207 (2000).
21. Morehouse LA, Sugarman ED, Bourassa PA, Milici AJ: The CETP-inhibitor torcetrapib raises HDL and prevents aortic atherosclerosis in rabbits. Presented at: The XVth International Symposium on Drugs Affecting Lipid Metabolism. Venice, Italy, 24-27 October 2004.
22. Matsuura F, Wang N, Chen W, Jiang XC, Tall AR: HDL from CETP-defcient subjects shows enhanced ability to promote cholesterol effux from macrophages in an apoE- and ABCG1-dependent pathway. J. Clin. Invest. 116(5), 1435-1442 (2006).
23. Yvan-Charvet L, Matsuura F, Wang N et al.: Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol effux to HDL. Arterioscler. Thromb. Vasc. Biol. 27(5), 1132-1138 (2007).
24. Barter PJ, Caulfeld M, Eriksson M et al.: Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357, 2109-2122 (2007).
25. Bloomfeld D, Carlson GL, Sapre A et al.: Effcacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am. Heart J. 157, 352-360 (2009).
26. Krishna R, Bergman AJ, Jin B et al.: Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Clin. Pharmacol. Ther. 84(6), 679-683 (2008).
27. Krishna R, Garg A, Jin B et al.: Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Br. J. Clin. Pharmacol. 68(4), 535-545 (2009).
28. Millar JS, Brousseau ME, Diffenderfer MR et al.: Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans. Arterioscler. Thromb. Vasc. Biol. 26(6), 1350-1356 (2006).
29. Eveland SS, Milot DP, Guo Q et al.: A high-precision fuorogenic cholesteryl ester transfer protein assay compatible with animal serum and 3456-well assay technology Anal. Biochem. 368(2), 239-249 (2007).
30. O'Neil E, Sparrow CP, Chen Y et al. Identifcation and characterization of anacetrapib (MK-0859): a novel CETP inhibitor. Presented at: XVI International Symposium on Drugs Affecting Lipid Metabolism. NY, USA, 4-7 October 2007.
31. Ranalletta M, Bierilo KK, Chen Y et al.: Biochemical characterization of cholesteryl ester transfer protein inhibitors. J. Lipid Res. 51(9), 2739-2752 (2010).
32. Kastelein JJP, van Leuven SI, Burgess L et al.; RADIANCE 1 Investigators: Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N. Engl. J. Med. 356, 1620-1630 (2007).
33. Nissen SE, Tardif J-C, Nicholls SJ et al.; ILLUSTRATE Investigators: Effect of torcetrapib on the progression of coronary atherosclerosis. N. Engl. J. Med. 356, 1304-1316 (2007).
34. Bots ML, Visseren FL, Evans GW et al.; RADIANCE 2 Investigators: Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 370, 153-160 (2007).
35. Brousseau ME, Schaefer EJ, Wolfe ML et al.: Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N. Engl. J. Med. 350, 1505-1515 (2004).
36. Forrest MJ, Bloomfeld D, Briscoe RJ et al.: Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br. J. Pharmacol. 154, 1465-1473 (2008).
37. Clerc RG, Stauffer A, Weibel F et al.: Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels. J. Hypertens. 28(8), 1676-1686 (2010).
38. Hu X, Dietz JD, Xia C et al.: Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition. Endocrinology 150(5), 2211-2219 (2009).
39. Blasi E, Bamberger M, Knight D et al.: Effects of CP-532,623 and torcetrapib, cholesteryl ester transfer protein inhibitors, on arterial blood pressure. J. Cardiovasc. Pharmacol. 53(6), 507-516 (2009).
40. Hollenberg NK: Direct renin inhibition and the kidney. Nat. Rev. Nephrol. 6(1), 49-55 (2010).
41. Hong Y, Dingemanse J, Mager DE: Pharmacokinetic/pharmacodynamic modeling of renin biomarkers in subjects treated with the renin inhibitor aliskiren. Clin. Pharmacol. Ther. 84(1), 136-143 (2008).
42. McMurray JJ, Pitt B, Latini R et al.; Aliskiren Observation of Heart Failure Treatment (ALOFT) Investigators: Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ. Heart Fail. 1(1), 17-24 (2008).
43. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators: Aliskiren combined with losartan in Type 2 diabetes and nephropathy. N. Engl. J. Med. 358(23), 2433-2446 (2008).
44. Parving HH, Brenner BM, McMurray JJ et al.: Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol. Dial. Transplant. 24(5), 1663-1671 (2009).
45. Lai E, Waters G, Tata J et al.: Effects of a niacin receptor partial agonist, MK-0354, on plasma free fatty acids, lipids, and cutaneous fushing in humans. J. Clin. Lipidol. 2(5), 375-383 (2008).
46. Littman B, Krishna R (Eds). Translational Medicine and Drug Discovery. Cambridge University Press, Cambridge, UK (2010) (In Press).